Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study
- Author
- GOODMAN, A. D1 ; COHEN, J. A2 ; CROSS, A3 ; VOLLMER, T4 ; RIZZO, M4 ; COHEN, R5 ; MORINUCCI, L5 ; BLIGHT, A. R5
[1] Department of Neurology, University of Rochester, Rochester, NY 14642, United States
[2] Department of Neurology, Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, United States
[3] Department of Neurology, Washington University, St Louis, MO 63110, United States
[4] Department of Neurology, Yale University, New Haven, CT 06520, United States
[5] Acorda Therapeutics, Inc, Hawthorne, NY 10532, United States - Source
Multiple sclerosis. 2007, Vol 13, Num 3, pp 357-368, 12 p ; ref : 29 ref
- Publisher
- Arnold, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- 4-aminopyridine Fampridine-SR clinical trial multiple sclerosis safety
- Keyword (fr)
- Amélioration Asthénie Complication Convulsion Céphalée Douleur Essai clinique Etude double insu Extrémité inférieure Fampridine Fatigue Forme libération contrôlée Hebdomadaire Homme Insomnie Maladie dégénérative Manuel Marche à pied Nausée Paresthésie Placebo Pronostic Prospective Questionnaire Résistance mécanique Sclérose en plaques Système nerveux pathologie Sécurité Tremblement Vertige Vitesse déplacement Locomotion Maladie inflammatoire Mouvement involontaire ORL pathologie Système nerveux central pathologie Trouble neurologique Trouble sensibilité Trouble sommeil Trouble équilibre
- Keyword (en)
- Improvement Asthenia Complication Convulsion Headache Pain Clinical trial Double blind study Lower extremity Fampridine Fatigue Controlled release form Weekly Human Insomnia Degenerative disease Manuals Walking Nausea Paresthesia Placebo Prognosis Prospective Questionnaire Strength Multiple sclerosis Nervous system diseases Safety Tremor Vertigo Speed Locomotion Inflammatory disease Involuntary movement ENT disease Central nervous system disease Neurological disorder Sensitivity disorder Sleep disorder Equilibrium disorder
- Keyword (es)
- Mejora Astenia Complicación Convulsión Cefalea Dolor Ensayo clínico Estudio doble ciego Extremidad inferior Fampridina Fatiga Forma liberación controlada Semanal Hombre Insomnio Enfermedad degenerativa Manual Caminata Nausea Parestesia Placebo Pronóstico Prospectiva Cuestionario Resistencia mecánica Esclerosis en placa Sistema nervioso patología Seguridad Temblor Vértigo Velocidad desplazamiento Locomoción Enfermedad inflamatoria Movimiento involuntario ORL patología Sistema nervosio central patología Trastorno neurológico Trastorno sensibilidad Trastorno sueño Trastorno equilibrio
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02Q Immunomodulators
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17F Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Neurology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18687095
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1177/1352458506069538 
https://dx.doi.org/10.1177/1352458506069538
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"357\";s:8:\"\u0000*\u0000epage\";s:3:\"368\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"GOODMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:11:\"COHEN, J. A\";i:1;s:8:\"CROSS, A\";i:2;s:10:\"VOLLMER, T\";i:3;s:8:\"RIZZO, M\";i:4;s:8:\"COHEN, R\";i:5;s:12:\"MORINUCCI, L\";i:6;s:12:\"BLIGHT, A. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Arnold\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"357\";s:8:\"\u0000*\u0000epage\";s:3:\"368\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"GOODMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:11:\"COHEN, J. A\";i:1;s:8:\"CROSS, A\";i:2;s:10:\"VOLLMER, T\";i:3;s:8:\"RIZZO, M\";i:4;s:8:\"COHEN, R\";i:5;s:12:\"MORINUCCI, L\";i:6;s:12:\"BLIGHT, A. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Arnold\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"357\";s:8:\"\u0000*\u0000epage\";s:3:\"368\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"GOODMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:11:\"COHEN, J. A\";i:1;s:8:\"CROSS, A\";i:2;s:10:\"VOLLMER, T\";i:3;s:8:\"RIZZO, M\";i:4;s:8:\"COHEN, R\";i:5;s:12:\"MORINUCCI, L\";i:6;s:12:\"BLIGHT, A. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Arnold\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"357\";s:8:\"\u0000*\u0000epage\";s:3:\"368\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"GOODMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:11:\"COHEN, J. A\";i:1;s:8:\"CROSS, A\";i:2;s:10:\"VOLLMER, T\";i:3;s:8:\"RIZZO, M\";i:4;s:8:\"COHEN, R\";i:5;s:12:\"MORINUCCI, L\";i:6;s:12:\"BLIGHT, A. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Arnold\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1177\/1352458506069538\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Multiple sclerosis\";s:9:\"\u0000*\u0000stitle\";s:11:\"Mult. scler\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"13\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"357\";s:8:\"\u0000*\u0000epage\";s:3:\"368\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1352-4585\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"GOODMAN\";s:10:\"\u0000*\u0000aufirst\";s:4:\"A. D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:11:\"COHEN, J. A\";i:1;s:8:\"CROSS, A\";i:2;s:10:\"VOLLMER, T\";i:3;s:8:\"RIZZO, M\";i:4;s:8:\"COHEN, R\";i:5;s:12:\"MORINUCCI, L\";i:6;s:12:\"BLIGHT, A. R\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:104:\"Fampridine-SR in multiple sclerosis : a randomized, double-blind, placebo-controlled, dose-ranging study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:6:\"Arnold\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
